EXTAVIA® (Interferon beta-lb) is a purified, sterile, lyophilized protein product produced by recombinant DNA techniques. Interferon beta-1b is manufactured by bacterial fermentation of a strain of Escherichia coli that bears a genetically engineered plasmid containing the gene for human interferon betaser17. The native gene was obtained from human fibroblasts and altered in a way that substitutes serine for the cysteine residue found at position 17. Interferon beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons. It does not include the carbohydrate side chains found in the natural material. EXTAVIA contains the same active ingredients as other Interferon beta-1b products. For this reason, these products should not be given concomitantly.
Extavia is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Published Studies Related to Extavia (Interferon Beta-1B)
Interferon beta for secondary progressive multiple sclerosis. 
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients
Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. [2011.08.30]
OBJECTIVE: To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon beta-1b (IFNbeta-1b)... CONCLUSIONS: Although NAb positivity was associated with increased brain MRI activity, no discernible effects on clinical outcomes were found. This finding may reflect the greater power of MRI compared with clinical outcomes to detect the treatment effects of IFNbeta-1b and may also result from temporal changes in NAb titers and biology.
Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]
OBJECTIVE: To compare interferon beta-1b (IFNbeta-1b) and glatiramer acetate (GA) on new lesion (NL) (gadolinium-enhancing, new T2) evolution into permanent black holes (PBH)--a marker of irreversible tissue damage--in patients with relapsing-remitting multiple sclerosis (RRMS)... CONCLUSION: IFNbeta-1b affected PBH development to a similar or better extent than GA. IFNbeta-1b favorably influences an MRI outcome indicative of permanent tissue destruction in the brains of patients with multiple sclerosis. Classification of evidence: This study provides Class III evidence that IFNbeta-1b is associated with a reduction in MRI PBH formation and evolution compared with GA between years 1 and 2 of treatment.
[Interferon beta for multiple sclerosis. How much is good enough?]. [2010.12]
Interferon beta-1b (IFNB-1b, Betaferon(R)) was the first therapy for multiple sclerosis (MS) showing efficacy in a randomized controlled clinical trial... In this review the BEYOND trial is reviewed and placed in the context of advantages and disadvantages of currently available first line therapies for MS.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. [2010.06.08]
OBJECTIVE: The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments... CONCLUSION: The results from the 16-Year Long-Term Follow-Up study support the long-term safety of interferon-beta-1b therapy in multiple sclerosis. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that patients with relapsing-remitting MS taking IFNbeta-1b 50 microg or 250 microg subcutaneously every other day for up to 5 years, with subsequent unspecified treatment, have fewer deaths after 16 years of follow-up than similar patients on placebo for up to 5 years, with subsequent unspecified treatment (risk difference 11.5%, 95% confidence interval 4-19).
Clinical Trials Related to Extavia (Interferon Beta-1B)
Physical Disability in Patients Treated With Betaferon [Recruiting]
To gather Observation data about physical disability progression, safety and adherence
during the use of Betaferon in daily practice. Patients with any type of Multiple Sclerosis
(MS) (MRRS) (PSMS), under treatment with Betaferon. Open Multicentric Observational study. 24
months. Evaluation of physical disability in patients treated with Betaferon, using Kurtzke's
expanded disability scale (EDSS) in biannual periods
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period [Recruiting]
The aim of the SEPLUS study is to evaluate the patients characteristics associated with
adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in
the BetaPlus program
Natalizumab De-escalation With Interferon Beta-1b [Recruiting]
Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young
adults. The management of MS-patients requires treatment with disease-modifying agents,
monoclonal antibodies such as natalizumab or immunosuppressants. Natalizumab showed good
efficacy and is approved for treatment of relapsing MS with a number of restrictions due to
safety issues. Cognitive data related to natalizumab treatment are still scarce.
Interferon-beta-1b is approved for high-frequency, subcutaneous (sc) administration in the
treatment of multiple sclerosis. It reduces the relapse rate, severity, hospitalisation and
the disease activity as seen on MRI.
This is a pilot study to explore the concept of de-escalating natalizumab treatment to
interferon-beta-1b e. o.d compared to continuous treatment with natalizumab in patients with
relapsing-remitting multiple sclerosis previously treated with natalizumab for 12 months.
The study is designed as prospective, controlled, randomized, rater-blinded, parallel-group,
two arm, mono-centric including patients of the Ticino Cohort. One arm will be treated with
Interferon-beta 1b 250mcg given subcutaneously every other day, the other with Natalizumab
300 mg given intravenously (i. v.), every four weeks. The treatment duration is 12 months,
the follow-up period 12 months. The time to first on-study relapse will be compared between
the to treatment arms (primary outcome). Other efficacy parameter include clinical and
radiological parameters, patient reported outcome on quality of life and fatigue. Safety is
assessed by reports of adverse events.
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea [Not yet recruiting]
This study is to describe the quality of life of Korean patients with early
relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon
with several validated questionnaires.
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis [Recruiting]
Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young
adults affecting approximately 1 in 1. 000 people in western countries. The clinical
manifestations usually begin at the age of 20 to 40 years with a median age of 28 years at
onset with acute episodes of neurological dysfunction, followed by periods of partial or
complete remission and clinical stability in between relapses. This relapsing-remitting
phase (RR-MS) of the disease is usually followed by progressive clinical disability
(secondary progressive phase, SP-MS).
At present, there is no cure for MS. Based on the pathological concept that
neuroinflammation is the common element leading or contributing to neurodegenerative
changes, immune interventions have been introduced into clinical practice such as
Natalizumab (Tysabri), a humanized monoclonal antibody. Natalizumab (Tysabri) is indicated
as a disease-modifying monotherapy of highly active relapsing MS. The associated risks,
especially progressive multifocal leukoencephalopathy, necessitate active monitoring of
patients and a continuous discussion of optimum use of this drug. In clinical practice, the
question how to manage patients on natalizumab at a higher risk for progressive multifocal
leukoencephalopathy remains unresolved.
This prospective, controlled (comparison to the period prior to natalizumab treatment),
single-arm, open-label, multi-centre, phase IV study aims to evaluating the concept of
natalizumab de-escalation to interferon-beta-1b e. o.d in relapsing-remitting multiple
sclerosis patients, who consider stopping natalizumab due to a benefit-risk assessment. In
particular, to evaluating if interferon beta-1b treatment may be able to overcome the
recurrence of significant clinical and radiological disease activity after natalizumab
cessation and may keep disease activity better under control as compared to the time prior
The study population includes patients with relapsing-remitting multiple sclerosis (RR-MS)
being treated at least for 12 months with natalizumab and having decided to stop natalizumab
treatment and to de-escalate their therapy to a first line treatment with interferon
beta-1b. They will be treated during 12 months with interferon-beta 1b 250 mcg given
subcutaneously every other day. A 12-month follow-up period with the same treatment is
Reports of Suspected Extavia (Interferon Beta-1B) Side Effects
Multiple Sclerosis Relapse (188),
Injection Site Erythema (124),
Injection Site Pain (87),
Gait Disturbance (72), more >>
Page last updated: 2013-02-10